Abstract
Background: HBV-HCC is heterogeneous and frequently contains multifocal tumors. To interrogate heterogeneity of HBV-HCC, we developed a HBV genome enriched single cell sequencing (HGE-scSeq) procedure and a computational method to identify HBV integration sites and infer DNA copy number variations (CNVs). Results: We performed HGE-scSeq on 269 cells from 4 tumor sites and 2 tumor thrombi of a HBV-HCC patient. HBV integrations were identified in 142 out of 269 (53%) cells sequenced, and were enriched in two HBV integration hot spots chr1:34,397,059 (CSMD2) and chr8:118,557,327 (MED30/EXT1). There were also 162 rare integration sites. HBV integration sites were enriched in DNA fragile sites and sequences around HBV integration sites were enriched for microhomologous sequences between human and HBV genomes. Cells were grouped into 4 clonal groups based on CNVs. The HBV integration heterogeneity was associated with single cell’s CNVs. All of 269 cells carried chromosome 1q amplification, a recurrent feature of HCC tumors, suggesting that 1q amplification occurred before HBV integration events in this case study. Further, we performed simulation studies to demonstrate that the sequential events (HBV infecting transformed cells) could result in the observed phenotype with biologically reasonable parameters. Conclusion: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs.
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with chronic Hepatitis B Virus (HBV) infection serving as a primary driver. A critical mechanism in HBV-mediated oncogenesis is the integration of viral DNA into the host genome, which can disrupt tumor suppressors or activate oncogenes. However, HCC is characterized by significant intra-tumor and inter-tumor heterogeneity. Traditional bulk sequencing methods obscure this complexity by averaging signals across millions of cells. To resolve the evolutionary trajectory and clonal structure of HBV-driven HCC, high-resolution single-cell genomic tools are required.
Methods: HGE-scSeq
To address the cost and technical challenges of single-cell whole-genome sequencing, we developed HBV Genome-Enriched Single-Cell Sequencing (HGE-scSeq). This method focuses sequencing depth on viral-human junctions while retaining sufficient genomic information to infer large-scale chromosomal changes.
The workflow involves:
- Single-Cell Isolation: 269 cells were isolated from four tumor sites (T1–T4) and two tumor thrombi in a single HBV-HCC patient. The MHCC97H cell line was used for method validation.
- Amplification and Enrichment: DNA was amplified via Multiple Displacement Amplification (MDA). Biotinylated HBV probes were then used to "capture" fragments containing viral sequences.
- Bioinformatics Pipeline: A custom pipeline was employed to identify true integration sites, filter technical artifacts, and infer Copy Number Variations (CNVs) from "off-target" reads. The method showed high correlation (0.85–0.92) with standard whole-genome sequencing.
Results
Viral Integration Landscape
HBV integrations were detected in 53% (142/269) of the sequenced cells. While 162 integration sites were "rare" (found in only one or two cells), two significant hotspots were identified: the CSMD2 gene (chr1) and the MED30/EXT1 region (chr8). These hotspots likely represent early integration events that provided a selective advantage to the resulting clones. Integration sites were notably enriched in genomic fragile sites and characterized by microhomology between the viral and human genomes.
Clonal Evolution and CNV Heterogeneity
Based on CNV profiles, the 269 cells were categorized into four distinct clonal groups. Clones 3 and 4 were predominantly found in the tumor thrombi, suggesting these lineages possessed enhanced invasive capabilities.
A pivotal finding was that chromosome 1q amplification—a hallmark of HCC—was present in every single cell analyzed. In contrast, specific HBV integrations were heterogeneous across the population. This suggests a specific evolutionary sequence in this patient: chromosomal instability (1q gain) likely preceded the viral integration events that further drove tumor progression.
Conclusion
HGE-scSeq provides a powerful, cost-effective framework for mapping the viral footprint in liver cancer at single-cell resolution. Our findings highlight the extreme heterogeneity of HBV-HCC and suggest that major genomic alterations can set the stage for subsequent viral-driven clonal expansion. Future studies across larger cohorts will determine if this "CNV-first" model is a general feature of HBV-driven hepatocarcinogenesis.
Summary updated